BRGX on OTC
BIOREGENX, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with J & Friends Holdings Ltd, TaoWeave, Inc. or GigaMedia Limited, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
81.1%Gross margin3
-67.1%Operating margin3
-83.2%Net margin3
-20.8%Revenue growth, 20253
$29.9KFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Nutritional brought in 87% of the revenue BIOREGENX, INC. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Nutritional | $1.8M | $1.6M |
| Medical Testing | $587.6K | $207.9K |
| Wellness Devices | $186.3K | $25.4K |
| Other Sales | $3.2K | $884 |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue13¢$350.9K
- Research and development1¢$31.8K
- Selling, general and admin75¢$2.0M
- Interest11¢$299.6K
Out of $1.9M in revenue.3 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending23¢$9.1K
- Kept or used elsewhere77¢$29.9K
Out of $39.0K of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Gross sales | $1.9M | $2.6M |
| Returns (Including common stock and warrants issued for refunds of $53,626 in 2024) | -$8.0K | -$261.7K |
| Net Sales | $1.9M | $2.3M |
| Cost of sales | $350.9K | $681.7K |
| Gross profit | $1.5M | $1.7M |
| Distributors incentives | $15.9K | $173.9K |
| Selling, general and administrative | $2.0M | $5.9M |
| Amortization expense | $0 | $2.2M |
| Impairment expense | $725.0K | $16.2M |
| Total operating expenses | $2.7M | $24.4M |
| Loss from operations | -$1.2M | -$22.8M |
| Interest expense and financing costs | -$299.6K | -$290.7K |
| Weighted average common shares outstanding - basic | 959.7M shares | 912.4M shares |
| Weighted average common shares outstanding - diluted | 959.7M shares | 912.4M shares |
| Loss per share - basic | $0.00 | -$0.03 |
| Loss per share - diluted | $0.00 | -$0.03 |
| Net Loss | -$1.5M | -$23.1M |
| Foreign currency translation adjustment | -$2.0K | $3.0K |
| Other comprehensive loss | -$1.5M | -$23.1M |
| Common stock and warrants issued for refunds, value | $53.6K |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $69.4K | $58.4K | $125.4K |
| Accounts receivable | $39.7K | $15.0K | |
| Inventories, net | $106.9K | $111.1K | |
| Prepaid expenses and other current assets | $35.2K | $123.3K | |
| Total current assets | $251.3K | $307.8K | |
| Property and equipment, net | $159.7K | $200.7K | |
| TOTAL ASSETS | $411.0K | $508.5K | |
| Accounts payable | $616.0K | $427.5K | |
| Accounts payable - related parties | $355.7K | $221.8K | |
| Accrued expenses | $434.4K | $453.0K | |
| Accrued interest - related party | $567.4K | $424.3K | |
| Notes payable and loans (including $522,500 in default) | $1.0M | $883.3K | |
| Notes payable and loans - related parties | $1.0M | $1.0M | |
| Deferred revenue | $60.2K | $197.0K | |
| Total current liabilities | $4.1M | $3.6M | |
| Royalty Liability | $700.0K | $0 | |
| Notes payable and loans, net of current | $181.8K | $254.6K | |
| TOTAL LIABILITIES | $4.9M | $3.9M | |
| Common stock, $0.001 par value; 1,500,000,000 shares authorized; 969,017,081 issued and outstanding as of December 31, 2025 and 956,994,100 as of December 31, 2024 | $969.0K | $957.0K | |
| Additional paid-in capital | $31.6M | $31.0M | |
| Common Stock issuable, -0- as of December 31, 2025 and 1,936,000 as of December 31, 2024 | $0 | $268.6K | |
| Accumulated deficit | -$37.1M | -$35.6M | |
| Accumulated other comprehensive income | $0 | $2.0K | |
| TOTAL STOCKHOLDERS' DEFICIT | -$4.5M | -$3.4M | -$2.1M |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $411.0K | $508.5K | |
| Debt Default, Short-Term Debt, Amount | $522.5K | ||
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.5B shares | 1.5B shares | |
| Common stock, shares issued | 969.0M shares | 957.0M shares | |
| Common stock, shares outstanding | 969.0M shares | 957.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$1.5M | -$23.1M |
| Depreciation and amortization | $75.1K | $2.2M |
| Amortization of debt discounts | $2.3K | $49.6K |
| Fair value of options issued to officers and directors for services | $0 | $2.9M |
| Impairment | $725.0K | $16.2M |
| Fair value of common shares issued for services | $380.7K | $842.7K |
| Interest capitalized to debt balance | $14.8K | $6.6K |
| Fair value of common shares issued as loan incentives | $6.9K | |
| Fair value of warrants issued for refunds | $0 | $19.4K |
| Accounts receivable | -$24.7K | $89.6K |
| Inventories | $4.2K | $106.4K |
| Prepaid expenses and other assets | $88.1K | $81.8K |
| Accounts payable | $188.5K | $185.8K |
| Accounts payable - related parties | $134.0K | $8.3K |
| Accrued expenses and other liabilities | -$18.6K | $59.7K |
| Accrued interest - related parties | $143.1K | $132.1K |
| Deferred Revenue | -$136.8K | -$135.0K |
| Net cash provided by (used in) operating activities | $39.0K | -$324.1K |
| Purchases of property and equipment | -$9.1K | -$189.4K |
| Purchases of Intangibles | -$50.0K | $0 |
| Cash acquired in DocSun transaction | $0 | $1.4K |
| Net cash used in investing activities | -$59.1K | -$187.9K |
| Note and loan payments | -$114.4K | -$48.2K |
| Increase in note and loan balances | $147.5K | $427.2K |
| Increase in note and loan balances - related parties | $0 | $63.2K |
| Net cash provided by financing activities | $33.1K | $442.1K |
| NET EFFECT OF EXCHANGE RATE FLUCTUATIONS | -$2.0K | $3.0K |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | $11.0K | -$67.0K |
| Interest | $58.1K | $94.4K |
| Income taxes | $0 | $0 |
| Fair value of common stock issued for intangible property and equipment in the acquisition of DocSun Biomedical Holdings, Inc. | $0 | $10.7M |
| Fair value of common stock issued upon acquisition of intangible property and goodwill in the merger with Findit, Inc. | $0 | $7.3M |
| Fair value of common stock and warrants issued for refunds offset to deferred revenue | $0 | $22.2K |
| Fair value of common stock and warrants issued for loan fees offset to loan discounts | $0 | $21.3K |
| Reclass of deposits to intangibles | $0 | $150.0K |
| Fair value of common stock and warrants issued for refunds offset to return reserve | $0 | $12.1K |
| Liability incurred upon acquisition of intangible | $750.0K | $0 |
Former names
Recent filings
- May 20, 202610-Q FORM 10-Q FOR MAR 2026
- May 15, 2026NT 10-Q EXTENSION
- Apr 15, 202610-K FORM 10-K FOR DEC 2025
- Apr 1, 2026NT 10-K EXTENSION
- Nov 14, 202510-Q FORM 10-Q FOR SEP 2025
- Aug 14, 202510-Q FORM 10-Q FOR JUNE 2025
- May 15, 202510-Q FORM 10-Q FOR MAR 2025
- Apr 16, 202510-K/A FORM 10-K FOR DEC 2024
- Apr 15, 202510-K FORM 10-K FOR DEC 2024
- Apr 14, 20258-K
- Apr 1, 2025NT 10-K
- Jan 22, 20258-K
- Jan 2, 20253
- Nov 14, 202410-Q FROM 10-Q FOR SEPT 2024
- Oct 11, 20248-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARBIOREGENX, INC. filings on SEC EDGAR
- 2SEC EDGARBIOREGENX, INC. filings on SEC EDGAR
- 3SEC EDGARBIOREGENX, INC. 10-K for fiscal 2025
- 4SEC EDGARBIOREGENX, INC. 10-K for fiscal 2021
- 5SEC EDGARBIOREGENX, INC. 10-K for fiscal 2022
- 6SEC EDGARBIOREGENX, INC. 10-K for fiscal 2023
- 7SEC EDGARBIOREGENX, INC. 10-Q for fiscal 2025
- 8SEC EDGARBIOREGENX, INC. 10-Q for fiscal 2025
- 9SEC EDGARBIOREGENX, INC. 10-Q for fiscal 2026